Is there room for non-dopaminergic treatment in Parkinson disease?

Abstract

Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

• Authors: Abraham Lieberman, Narayanan Krishnamurthi
• Journal: Journal of neural transmission (Vienna, Austria : 1996) (J Neural Transm (Vienna)) Vol. 120 Issue 2 Pg. 347-8 (Feb 2013) ISSN: 1435-1463 [Electronic] Austria
• PMID: 23242741 (Publication Type: Journal Article)

Chemical References

• Antiparkinson Agents
• Piperidines
• Urea
• Droxidopa
• pimavanserin

Topics

• Antiparkinson Agents (therapeutic use)
• Droxidopa (therapeutic use)
• Humans
• Parkinson Disease (drug therapy)
• Piperidines (therapeutic use)
• Treatment Outcome
• Urea (analogs & derivatives, therapeutic use)